[go: up one dir, main page]

WO2025168015A1 - Utilisation d'un analogue de nucléoside antiviral dans la préparation d'un médicament pour le traitement de coronavirus félins - Google Patents

Utilisation d'un analogue de nucléoside antiviral dans la préparation d'un médicament pour le traitement de coronavirus félins

Info

Publication number
WO2025168015A1
WO2025168015A1 PCT/CN2025/076086 CN2025076086W WO2025168015A1 WO 2025168015 A1 WO2025168015 A1 WO 2025168015A1 CN 2025076086 W CN2025076086 W CN 2025076086W WO 2025168015 A1 WO2025168015 A1 WO 2025168015A1
Authority
WO
WIPO (PCT)
Prior art keywords
combination
pharmaceutically acceptable
use according
acceptable salt
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/076086
Other languages
English (en)
Chinese (zh)
Inventor
黄萌胜
刘学明
曹春来
梁焕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Bio Technology Hengqin Co Ltd
Zhuhai United Bio Pharmaceutical Co Ltd
Original Assignee
United Bio Technology Hengqin Co Ltd
Zhuhai United Bio Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Bio Technology Hengqin Co Ltd, Zhuhai United Bio Pharmaceutical Co Ltd filed Critical United Bio Technology Hengqin Co Ltd
Priority to CN202580001882.XA priority Critical patent/CN120981237A/zh
Publication of WO2025168015A1 publication Critical patent/WO2025168015A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Definitions

  • the invention belongs to the field of antiviral drugs, and in particular relates to use of an antiviral nucleoside analog in preparing a drug for treating feline coronavirus.
  • the hepatitis C virus belongs to the Flaviviridae family, and the mechanism of action of sofosbuvir is to specifically bind to the NS5B protein of the hepatitis C virus to prevent the replication of the virus.
  • sofosbuvir has an extremely high cure rate and is extremely safe, but it has not yet been successfully applied to other types of antiviral treatments. Due to the different types of viruses and different pathogenic mechanisms, sofosbuvir cannot theoretically be successfully used to treat different types of viruses.
  • the present invention provides an antiviral nucleoside analogue represented by general formula (I) or a pharmaceutically acceptable salt thereof for use in preparing a medicament for treating or preventing feline coronavirus.
  • R1 is hydrogen, deuterium, n-alkyl, branched alkyl, cycloalkyl, or phenyl; as one embodiment, one or more H in the phenyl group may be optionally substituted by at least one of the following substituents: alkyl, alkenyl, alkynyl, alkoxy, F, Cl, Br, I, nitro, cyano, haloalkyl, N(R1′) 2 , C 1-6 acylamino, -NHSO 2 , C 1-6 alkyl, or -SO 2 ; R1′ is independently hydrogen or alkyl;
  • R 2 is hydrogen, deuterium, or alkyl
  • R 3 and R 4 are hydrogen, deuterium, n-alkyl, branched alkyl, haloalkyl, halogen, alkenyl, alkynyl, cycloalkyl, cyano, alkoxy, aryl, or heterocyclic group;
  • R 5 is hydrogen, deuterium, alkyl, halogen, amino, nitro, hydroxy, cyano, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, heterocyclylalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
  • the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof is used in the preparation of a drug for treating or preventing feline enteric coronavirus.
  • the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof is used in the preparation of a drug for treating or preventing feline infectious peritonitis virus.
  • the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof is used in the preparation of a drug for treating or preventing feline infectious peritonitis.
  • the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof includes its isotopes, stereoisomers, tautomers, esters or amides.
  • the antiviral nucleoside analog represented by formula (I) or a pharmaceutically acceptable salt thereof is selected from the compound represented by formula (Ia) (also known as sofosbuvir):
  • the disease caused by the feline coronavirus infection of the present invention is feline infectious peritonitis caused by feline infectious peritonitis virus.
  • the effective dose of the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof is 0.1-500 mg/kg;
  • the pharmacologically effective dose of the compound of formula (Ia) is 0.1-500 mg/kg.
  • the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof is used in combination with "other antiviral drugs”.
  • antiviral drugs refer to antiviral drugs other than the antiviral nucleoside analogs represented by general formula (I) or pharmaceutically acceptable salts thereof, and the other antiviral drugs include but are not limited to remdesivir, elbavir, ravidasvir, monolavir, tenofovir, entecavir, parovird, olfosbuvir, grazoprevir, voxilaprevir, mindevir, azithromycin, favipiravir, senoxan, leretovir, benoforvir, ensetvir, clopavir, danoprevir or imipenem, or a combination of two or more thereof.
  • antiviral nucleoside analog represented by general formula (Ia) or a pharmaceutically acceptable salt thereof is used in combination with "other antiviral drugs”.
  • the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof, or the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof is combined with other antiviral drugs in the form of a pharmaceutical composition, and the pharmaceutical composition comprises: an effective dose of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a combination of an antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof and other antiviral drugs, and pharmaceutically acceptable excipients.
  • the present invention provides a pharmaceutical composition for treating or preventing diseases caused by feline coronavirus infection, wherein the pharmaceutical composition comprises sofosbuvir.
  • the pharmaceutical composition of the present invention generally contains 0.1 to 100% by weight of the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof; as one embodiment, the antiviral nucleoside analog represented by general formula (I) or a pharmaceutically acceptable salt thereof in a unit dosage form generally contains 0.1 to 500 mg.
  • composition of the compounds of this invention can be prepared according to methods well known in the art. When used for this purpose, if necessary, the compounds of this invention can be combined with one or more solid or liquid pharmaceutical excipients and/or adjuvants to make suitable application forms or dosage forms for veterinary use.
  • the compound of the present invention or the pharmaceutical composition containing the same can be administered in a unit dosage form.
  • the main routes of administration are oral administration and injection. If necessary, other routes can be used, such as intestinal administration, peritoneal administration, mucosal administration, vaginal administration or rectal administration.
  • the dosage form can be a liquid, semisolid, or solid dosage form.
  • liquid dosage forms can be true solutions, colloids, microparticles, emulsions, or suspensions.
  • Other dosage forms include tablets, capsules, pellets, pills, powders, solutions, emulsions, granules, and suppositories.
  • the compound of the present invention can be prepared into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle delivery systems.
  • the dosage form can be prepared as an injection, and various solvents and additives known in the art can be widely used to prepare solutions, suspensions, emulsions, and freeze-dried powder injections.
  • Such preparations can be aqueous or non-aqueous and can contain one or more pharmacologically acceptable carriers, diluents, binders, lubricants, preservatives, surfactants, dispersants, osmotic pressure regulators, solubilizers, and pH regulators.
  • the diluent can be water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene isostearyl alcohol, polyoxyethylene sorbitol esters, fatty acid esters, or a combination of two or more thereof.
  • the osmotic pressure regulator can be sodium chloride, mannitol, glycerol, glucose, phosphate, acetate, etc., or a combination of two or more thereof; the solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl ⁇ -cyclodextrin, etc., or a combination of two or more thereof; the pH regulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc., or a combination of two or more thereof. If a lyophilized powder injection is prepared, mannitol, glucose, etc., or a combination of the two can also be added as a support. In addition, if necessary, colorants, preservatives, spices, flavoring agents, sweeteners, or spices can also be added to the pharmaceutical preparation. These excipients are commonly used in the art.
  • carriers include diluents and absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate, etc., or a combination of two or more thereof; wetting agents and binders, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinyl pyrrolidone, etc., or a combination of two or more thereof; disintegrants, such as dry starch, Alginate, agar powder, brown seaweed starch, sodium bicarbonate and citric acid, calcium
  • carriers include diluents and absorbents such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, glyceryl monostearate, kaolin, talc, or combinations of two or more thereof; binders such as gum arabic, tragacanth gum, gelatin, ethanol, honey, liquid sugar, rice paste, or flour paste, or combinations of two or more thereof; and disintegrants such as agar powder, dry powder, alginate, sodium lauryl sulfate, methylcellulose, ethylcellulose, or combinations of two or more thereof.
  • diluents and absorbents such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, glyceryl monostearate, kaolin, talc, or combinations of two or more thereof
  • binders such as gum arabic, tragacanth gum, gelatin, ethanol, honey, liquid sugar
  • the active ingredient compound of the present invention such as sofosbuvir
  • the various carriers described above are mixed with the various carriers described above, and the resulting mixture is placed in a hard gelatin capsule or soft capsule.
  • the active ingredient compound of the present invention may be formulated into microcapsules, suspended in an aqueous medium to form a suspension, which may be encapsulated in a hard capsule or formulated as an injection.
  • the sterile media used in the present invention can be prepared by standard techniques well known to those skilled in the art. They can be sterilized, for example, by filtering through a bacterial filter, by adding a sterilizing agent to the composition, by irradiating the composition, or by heating the composition. They can also be prepared into sterile injectable media immediately prior to use.
  • the medicaments or pharmaceutical compositions of the present invention can be administered using any known method of administration.
  • the optimal route of administration for administering the compounds of the present invention will, of course, depend on the disease and the site of treatment. Because the pharmacokinetic and pharmacodynamic characteristics of the compounds of the present invention vary to some extent, the most preferred method for achieving therapeutic concentrations in tissues is to gradually increase the dosage and monitor the clinical effects. For such gradually increasing therapeutic doses, the initial dose will depend on the route of administration.
  • the dosage of the pharmaceutical compositions of the compounds of the present invention administered to any particular patient depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, personality and individual response of the patient or animal, the route of administration, the number of doses, and the purpose of the treatment. Therefore, the therapeutic dosage of the present invention may vary widely. Depending on the condition of the patient being treated, some variation in dosage may be necessary, and in all cases, the physician will determine the appropriate dosage for an individual patient.
  • the compound or composition of the present invention can be taken alone, or used in combination with other therapeutic drugs or symptomatic drugs and the dosage can be adjusted.
  • sofosbuvir as an anti-hepatitis C virus compound, can effectively achieve the effect of resisting feline infectious peritonitis virus, and can treat and improve various symptoms of feline infectious peritonitis caused by feline infectious peritonitis virus.
  • all cases were cured after receiving treatment for no more than 14 days, and no recurrence or treatment-related adverse reactions were found in the follow-up after treatment. It has the advantages of short treatment cycle, high therapeutic index, and high safety.
  • sofosbuvir as an anti-hepatitis C virus compound, can effectively treat feline infectious peritonitis cases, eliminate feline coronavirus in the case, and can treat and improve various symptoms of feline infectious peritonitis caused by feline infectious peritonitis virus, and improve physiological and biochemical indicators.
  • all cases were cured after receiving treatment for no more than 21 days, and no recurrence or treatment-related adverse reactions were found in the follow-up after treatment. It has the advantages of short treatment cycle, high therapeutic index, and high safety.
  • the treatment of cases suffering from feline infectious peritonitis shows that sofosbuvir can safely and effectively treat various symptoms caused by feline infectious peritonitis, eliminate feline infectious peritonitis virus in the body, and restore body functions (for example, body temperature returns to normal, weight gradually increases, and white-globulin ratio gradually increases to above 0.6). It has the advantages of short treatment cycle, high therapeutic index, and high safety. No drug-related adverse reactions occur during treatment, and no recurrence or related adverse reactions are found after long-term follow-up.
  • the present invention can fill the gap in feline infectious peritonitis drugs in the veterinary drug market and has broad market application value prospects.
  • Figure 1 Chest and abdominal X-rays before and after Lanbei treatment. A and B are before treatment, and C and D are after treatment.
  • Figure 2 Chest and abdominal X-rays before and after treatment with Laifu. A and B are before treatment, and C and D are after treatment.
  • Example 1 Determination of the antiviral effect of sofosbuvir using different cell lines in vitro
  • sofosbuvir solutions were added to the relevant groups, with 5 replicates for each group.
  • the virus control group was added with equal amounts of solution without sofosbuvir but containing equal amounts of virus.
  • the blank control group received an equal volume of a solution containing neither sofosbuvir nor virus.
  • Each well contained 0.1% DMSO.
  • the cells were incubated for 48 hours. After 48 hours, viral inhibition was measured using the CCK8 assay.
  • Example 2 Intravenous administration of sofosbuvir to treat cases of feline infectious peritonitis
  • Sofosbuvir intravenous injection was prepared by pharmaceutically feasible means, and the preparation method was as follows: 5g of pharmaceutical grade sofosbuvir compound was weighed, placed on a magnetic stirrer, water for injection was added, a pH regulator was added to stabilize the pH at 6.5-7.0, and the solution was diluted to 1L. The final concentration of sofosbuvir was 5mg/mL.
  • sofosbuvir intravenous injection was filtered using a 0.22 ⁇ m filter membrane in a biological safety cabinet and packaged into a sterile, pyrogen-free container for use. 5-40mg/kg was preferably administered for treatment during clinical treatment. Preferably, according to body weight, after calculating the dosage, each case was divided into two injections per day for treatment. During the treatment, the symptoms and physiological and biochemical indicators of the cats were observed. Other manifestations included loss of appetite, poor spirits, weight loss, and continued recurrent fever.
  • Example 3 Subcutaneous and oral administration of sofosbuvir in the treatment of feline infectious peritonitis
  • Sofosbuvir subcutaneous injection and sofosbuvir oral tablets were prepared by pharmaceutically feasible means, and 5-60 mg/kg was preferably administered for treatment during clinical treatment.
  • Preparation of sofosbuvir subcutaneous injection Use pharmaceutical grade PEG 400 for injection and water for injection to prepare a 20% (v/v) PEG400 solution as a solvent.
  • sofosbuvir compound Use pharmaceutical grade sofosbuvir compound, add solvent to dissolve thoroughly, add a pH regulator to stabilize the pH at 6.5-7.0, add 20% PEG solution to the solution and make the volume to 250 mL, so that the final concentration of sofosbuvir is 40 mg/mL.
  • sofosbuvir oral tablets Weigh 15g of pharmaceutical grade sofosbuvir compound, 13.62g of pharmaceutical grade mannitol, 11.38g of microcrystalline cellulose, 1.12g of cross-linked carboxymethyl cellulose sodium, 0.22g of colloidal silicon dioxide, and 0.34g of magnesium stearate and place them in a mixer. Stir thoroughly and evenly, place the mixed powder in a tablet press, control the tablet weight to 0.208g, and compress 200 sofosbuvir oral tablets. The oral tablets are placed in a pharmaceutical packaging bottle for use.
  • each case is divided into two subcutaneous injections per day for treatment on days 0-14.
  • Oral tablets are given to support stable improvement of case symptoms on days 15-21.
  • the symptoms and physiological and biochemical indicators of the cats are observed.
  • Other manifestations include loss of appetite, poor spirits, weight loss, and persistent and recurrent fever.
  • Example 4 Subcutaneous injection of sofosbuvir clears the virus from the body and cures a case of feline infectious peritonitis
  • this example recruited 8 cases of feline infectious peritonitis.
  • wet feline infectious peritonitis required ascites to be tested positive for feline infectious peritonitis virus by qPCR before inclusion in treatment
  • dry feline infectious peritonitis required fine needle aspiration of the mesenteric lymph node and then tested positive for feline infectious peritonitis virus by qPCR before inclusion in treatment.
  • various physiological and biochemical indicators and changes in serum amyloid protein (SAA) were tested, changes in viral load during treatment were monitored, and the clinical manifestations of the cats were observed. Changes in the chest and abdomen were observed by X-ray imaging before and after treatment.
  • the administration method was subcutaneous injection, and sofosbuvir was administered twice a day.
  • the preparation of sofosbuvir subcutaneous injection was the same as that in Example 3.
  • the time of enrollment was recorded as D0.
  • Table 6 shows the viral load of feline infectious peritonitis patients during treatment. Seven of the eight patients tested negative for the virus after treatment and were discharged. Case Guaiguai's viral load decreased during treatment, but due to his frail condition, he was unable to sustain further treatment after a week and died on Day 8.
  • Table 7 shows the results of serum amyloid protein (SAA) treatment. This level can be abnormally elevated in cats with infectious peritonitis or other inflammatory conditions. After sofosbuvir treatment, 6/8 cases showed effective improvement and reduction. However, one/8 cases experienced a broken hind leg upon entry and exit from the group, which the veterinarian determined was the cause of the elevated SAA level at the end of the group.
  • SAA serum amyloid protein
  • Table 8 shows the albumin/globulin (A/G) ratio.
  • albumin levels are low and globulin levels are high, resulting in a decreased A/G ratio.
  • 6/8 cases showed significant recovery, reaching 0.6 or higher. Hairballs, due to a broken leg, did not experience a significant increase in the A/G ratio.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un analogue de nucléoside antiviral représenté par la formule générale (I) dans la préparation d'un médicament pour le traitement ou la prévention d'infections à coronavirus félin. L'analogue de nucléoside antiviral peut inhiber efficacement les coronavirus félins, et présente des cycles de traitement courts, un indice thérapeutique élevé et une bonne sécurité.
PCT/CN2025/076086 2024-02-08 2025-02-07 Utilisation d'un analogue de nucléoside antiviral dans la préparation d'un médicament pour le traitement de coronavirus félins Pending WO2025168015A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202580001882.XA CN120981237A (zh) 2024-02-08 2025-02-07 抗病毒核苷类似物在制备治疗猫冠状病毒药物中的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202410176277.3 2024-02-08
CN202410176277 2024-02-08

Publications (1)

Publication Number Publication Date
WO2025168015A1 true WO2025168015A1 (fr) 2025-08-14

Family

ID=96699228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/076086 Pending WO2025168015A1 (fr) 2024-02-08 2025-02-07 Utilisation d'un analogue de nucléoside antiviral dans la préparation d'un médicament pour le traitement de coronavirus félins

Country Status (2)

Country Link
CN (1) CN120981237A (fr)
WO (1) WO2025168015A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110869028A (zh) * 2017-03-14 2020-03-06 吉利德科学公司 治疗猫冠状病毒感染的方法
US20220380347A1 (en) * 2020-04-17 2022-12-01 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2023044171A1 (fr) * 2021-09-20 2023-03-23 Pardes Biosciences, Inc. Inhibiteurs de cystéine protéases et leurs méthodes d'utilisation
US20230234984A1 (en) * 2022-01-21 2023-07-27 Anixa Biosciences, Inc. Cysteine protease inhibitors and methods of use thereof
CN117440961A (zh) * 2022-04-25 2024-01-23 北京沐华生物科技有限责任公司 用于治疗或预防冠状病毒感染的核苷类药物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110869028A (zh) * 2017-03-14 2020-03-06 吉利德科学公司 治疗猫冠状病毒感染的方法
US20220380347A1 (en) * 2020-04-17 2022-12-01 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2023044171A1 (fr) * 2021-09-20 2023-03-23 Pardes Biosciences, Inc. Inhibiteurs de cystéine protéases et leurs méthodes d'utilisation
US20230234984A1 (en) * 2022-01-21 2023-07-27 Anixa Biosciences, Inc. Cysteine protease inhibitors and methods of use thereof
CN117440961A (zh) * 2022-04-25 2024-01-23 北京沐华生物科技有限责任公司 用于治疗或预防冠状病毒感染的核苷类药物及其用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KHAN MOHD YASIR, SHAH ABID ULLAH, DURAISAMY NITHYADEVI, MOAWAD NADINE, ELALAOUI REDA NACIF, CHERKAOUI MOHAMMED, HEMIDA MAGED GOMAA: "Applications of some artificial intelligence tools in the drug design of some compounds targeting the main viral protease of the Feline Infectious Peritonitis Virus (FIPV) in cats", BIORXIV, 10 September 2024 (2024-09-10), pages 1 - 30, XP093342664, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2024.09.09.612092v1.full.pdf> DOI: 10.1101/2024.09.09.612092 *
MAURIZIO QUINTILIANI, LEENTJE PERSOONS, NICOLA SOLAROLI, ANNA KARLSSON, GRACIELA ANDREI, ROBERT SNOECK, JAN BALZARINI, CHRISTOPHER: "Design, synthesis and biological evaluation of 2?-deoxy-2?,2?-difluoro-5-halouridine phosphoramidate ProTides", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 19, no. 14, 1 July 2011 (2011-07-01), pages 4338 - 4345, XP055016528, ISSN: 09680896, DOI: 10.1016/j.bmc.2011.05.037 *
MEHELLOU, Y. ; VALENTE, R. ; MOTTRAM, H. ; WALSBY, E. ; MILLS, K.I. ; BALZARINI, J. ; MCGUIGAN, C.: "Phosphoramidates of 2'-?-D-arabinouridine (AraU) as Phosphate Prodrugs; Design, Synthesis, in vitro Activity and Metabolism", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 18, no. 7, 1 April 2010 (2010-04-01), AMSTERDAM, NL, pages 2439 - 2446, XP027027250, ISSN: 0968-0896 *
NOURIAN ANAHID, KHALILI, HOSSEIN: "Sofosbuvir as a potential option for the treatment of COVID-19", ACTA BIOMED, vol. 91, 1 January 2000 (2000-01-01), pages 239 - 241, XP055778383 *
SHABANI M., SADEGH EHDAEI B., FATHI F., DOWRAN R.: "A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019", NEW MICROBES AND NEW INFECTIONS, vol. 42, 1 January 2021 (2021-01-01), GB , pages 1 - 4, XP093342670, ISSN: 2052-2975, DOI: 10.1016/j.nmni.2021.100895 *

Also Published As

Publication number Publication date
CN120981237A (zh) 2025-11-18

Similar Documents

Publication Publication Date Title
JP6929785B2 (ja) 貧血治療のための組成物及び方法
CN1181009A (zh) 在哺乳动物中抑制病毒和肿瘤生长的含n－氯苯基甲氨酸化合物、n－氯苯基硫代甲氨酸化合物和n－膦酰甘氨酸衍生物的药物组合物
EP4241771A2 (fr) Méthodes et compositions permettant de traiter la septicémie
WO2016173486A1 (fr) Utilisation de triméthazine dans la préparation de médicaments pour la prévention et le traitement de maladies hépatiques
TW201306839A (zh) 治療ｈｃｖ感染之組合療法
BR112020018601A2 (pt) Regime de dosagem de modulador de montagem de capsídeo
TW469132B (en) Antiviral combinations
WO2013071696A1 (fr) Utilisation de cinq bases normales chez l&#39;homme pour la préparation de médicaments antitumoraux
RU2367442C2 (ru) Способ нормализации мочеиспускания при нарушении функции почек
US3705946A (en) Method of treating hyperuricemia
WO2025218456A1 (fr) Utilisation de baloxavir sodique dans le traitement d&#39;une infection par le virus de la fièvre hémorragique de crimée-congo
PL190505B1 (pl) Kompozycja farmaceutyczna i sposób jej wytwarzania
WO2025168015A1 (fr) Utilisation d&#39;un analogue de nucléoside antiviral dans la préparation d&#39;un médicament pour le traitement de coronavirus félins
US12427125B2 (en) Method for treating SARS and treating or preventing ARDS
US20230270724A1 (en) PDE3 inhibitors for treating viral infections
US5955498A (en) Agent for prophylaxis and therapy of diseases
CN114588159A (zh) 一种治疗猫冠状病毒感染的化合物及其应用
WO2021224494A1 (fr) Nouveaux traitements d&#39;infections virales
JPH11508247A (ja) ウベニメクス及びウベニメクスを含む医薬組成物のウイルス性肝炎の治療薬としての用途
TW202339727A (zh) 使用１ｈ－１，２，３－三唑－４－羧酸之治療方法
JPH04108731A (ja) 抗エイズウイルス剤
CN115089582B (zh) 阿昔替尼在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
RU2825648C1 (ru) Способы лечения коронавирусных инфекций
RU2464984C2 (ru) Нестероидное противовоспалительное лекарственное средство
CN120695022A (zh) 肌苷在制备预防和/或治疗子痫前期药物中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25751614

Country of ref document: EP

Kind code of ref document: A1